VALIDATION OF A 1ST-GENERATION EPSTEIN-BARR VIRUS-VACCINE PREPARATION SUITABLE FOR HUMAN USE
VALIDATION OF A 1ST-GENERATION EPSTEIN-BARR VIRUS-VACCINE PREPARATION SUITABLE FOR HUMAN USE
复制标题
DOI：
10.1002/jmv.1890290114
复制
发表时间：
1989-09-01
影响因子：
12.7
通讯作者：
EPSTEIN, MA
中科院分区：
文献类型：
--
作者：
MORGAN, AJ;ALLISON, AC;EPSTEIN, MA
研究了一种新的EB病毒疫苗制剂在棉顶罗望子中的免疫效果。该疫苗由快速蛋白液相层析纯化的340kD EB病毒膜抗原糖蛋白(MA Gp340)与合成的含有Pluronic聚合物的角鲨烷乳化的壁壁酰二肽佐剂混合而成，既适合大规模批量生产，也适合最终给人接种。接种的罗望子素迅速发展出可检测到的针对MA gp340的高滴度抗体，它们的血清对EB病毒具有很强的中和力。在与大量100%致癌剂量的EB病毒攻击后，与对照动物相比，接种罗望子素的循环中携带EB病毒的单核细胞水平显著降低，并且完全没有肿瘤。因此，这种第一代疫苗已经在实验动物中得到验证，并为第一阶段的人体试验开辟了道路。
The efficacy of a new vaccine preparation against Epstein-Barr (EB) virus was investigated in cotton-top tamarins. The vaccine consists of fast protein liquid chromatography-purified EB virus membrane antigen glycoprotein of 340 Kd (MA gp340) mixed with a synthetic muramyl dipeptide adjuvant emulsified in squalane containing a pluronic polymer; it is suitable for both scaled-up batch production and eventual administration to man. Vaccinated tamarins rapidly developed ELISA detectable high titre antibodies to MA gp340, and their sera became strongly EB virus-neutralising. After challenge with a massive 100% carcinogenic dose of EB virus, the vaccinated tamarins had a strikingly low level of circulating EB virus-carrying mononuclear cells, in contrast to a control animal, and remained entirely free of tumours. This first-generation vaccine has thus been validated in experimental animals and the way opened for a phase I human trial.